| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
The world seemed to come to a momentary halt on December 8, 1980, when news that John Lennon was shot and killed as he approached his apartment building in New York City came out. Lennon’s untimely death sent shockwaves around the world. His contributions to music, activism and peace continue to inspire generations.
As we mark 43 years since Lennon's passing, his legacy as a pioneering musician, activist and symbol of peace endures. But another aspect of Lennon's life that warrants attention is his relationship with psychotropic and psychedelic substances, particularly cannabis and LSD, which played a significant role in both his creative process and personal life.
A COMPASS Pathways (NASDAQ:CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provided preliminary data on the treatment’s safety and efficacy.
Published by the Journal of the American Medical Association (JAMA Psychiatry), the pilot study’s findings suggest Safe of one 25mg dose of the biotech’s synthetic psilocybin COMP360 paired with psychotherapy for treating the mentioned mental health condition, a “treatment-resistant cyclical mood disorder” commonly associated with debilitating and difficult-to-treat depressive episodes. Read more HERE.
Congressional lawmakers from both sides of the aisles and in both chambers agreed upon a large-scale defense bill that includes funding psychedelic studies for military service members.
The report on the 2024 National Defense Authorization Act (NDAA) released on Dec. 6 shows it includes the House GOP-led version of the bill containing the psychedelics research provision. A section creating a medical cannabis pilot program for veterans was finally withdrawn. More HERE.
The latest San Francisco 49ers and Philadelphia Eagles match (42-19) brought on additional highlights on players’ charity choices for the NFL “My Cleats, My Cause” campaign. This week's NFL game between the San Francisco 49ers and the Philadelphia Eagles brought additional excitement to the field thanks to 49ers’ Offensive Lineman Jon Feliciano who announced his support for the Multidisciplinary Association for Psychedelic Studies (MAPS). Find out more HERE.
Meanwhile, supermodel Chrissy Teigen recently celebrated her 38th birthday surrounded by her loved ones and ketamine therapy. Via her Instagram account, she said the psychedelic session made her see “space and time” as well as baby Jack “and some weird penguins,” and that she “cried and cried and cried.”
Teigen previously opened up about her pregnancy loss in Sept. 2020, a child that she and husband John Legend had named Jack. Keep reading HERE.
Braxia Scientific's (OTC:BRAXF) Q2 2024 shows cash burn’s over but income low, what's next for the company?
Check out nonprofit Drugs and Me’s new AI tool for clearing up questions and concerns about controlled substances.
EXCLUSIVE - Coca leaf, extract, cocaine & Safe Supply: Grasping potentials with sector incubator's president, Ronan Levy.
See Also: Last Week's Edition Of 'Psyched'
AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, Dec. 4 at $1.37, lower than immediately prior opening (Nov. 27 at $1.43) yet still higher than former weeks’ openings at $1.25 and $1.29
On Friday, Dec. 8, it closed at $1.33, the same as immediately prior to closing (Dec. 1,) vs. former weeks’ closings at $1.42 and $1.32.
Week’s highest was $1.41 (at times during Monday and Thursday,) vs. prior weeks’ highest at $1.43, $1.44 and $1.37.
Week’s lowest was $1.28 (on Tuesday,) vs. prior weeks’ lowest points at $1.27, $1.25 and $1.27.
COMPASS Pathways (NASDAQ:CMPS) closed at $6.47, vs. prior closings at $6.10, $6.46 and $6.01.
GH Research (NASDAQ:GHRS) closed at $5.98, a drop as of prior closings at $6.40, $6.58 and $6.44.
Incannex Healthcare (NASDAQ:IXHL) closed at $5.53, still mounting from the prior closing at $5.23, and most noticeably two weeks’ past ones at $0.97 and $0.91.
Clearmind Medicine (NASDAQ:CMND) closed at $3.30, falling from last week’s close at $4.14, yet still higher than former weeks’ closings at $3.10 and $3.82.
Mind Medicine (MindMed) (NASDAQ:MNMD) closed at $3.21, down from the prior closing at $3.52, yet still higher than former weeks’ ones at $3.03 and $2.59.
Seelos Therapeutics (NASDAQ:SEEL) closed at $1.66, jumping from the former week’s closing at $1.38, yet still below immediately prior closings at $3.21 and $3.82.
Bright Minds Biosciences (NASDAQ:DRUG) closed at $1.56, jumping from former weeks’ closings at $1.42, $1.49 and $1.26, respectively.
Enveric Biosciences (NASDAQ:ENVB) closed at $1.52, falling from last week’s close at $1.68, yet still higher or the same as immediately prior closings at $1.47 and $1.52.
Silo Pharma (NASDAQ:SILO) closed at $1.50, a slight uptake as of the former week’s closing at $1.45, plus other immediately prior closings at $1.82 and $1.50.
Atai Life Sciences (NASDAQ:ATAI) closed at $1.21, an uptake as of prior weeks’ closings at $1.12, $1.09 and $1.11.
Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform helping you invest smarter - Come join us and see for yourself!
Posted In: ATAI BRAXF CMND CMPS DRUG ENVB GHRS IXHL MNMD PSIL SEEL SILO
